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Cancer is a heterogeneous disease often requiring a complexity of alterations to drive a normal cell to a malignancy
and ultimately to a metastatic state. Certain genetic perturbations have been implicated for initiation and progression.
However, to a great extent, underlying mechanisms often remain elusive. These genetic perturbations are most likely
reflected by the altered expression of sets of genes or pathways, rather than individual genes, thus creating a need for
models of deregulation of pathways to help provide an understanding of the mechanisms of tumorigenesis. We
introduce an integrative hierarchical analysis of tumor progression that discovers which a priori defined pathways are
relevant either throughout or in particular steps of progression. Pathway interaction networks are inferred for these
relevant pathways over the steps in progression. This is followed by the refinement of the relevant pathways to those
genes most differentially expressed in particular disease stages. The final analysis infers a gene interaction network for
these refined pathways. We apply this approach to model progression in prostate cancer and melanoma, resulting in a
deeper understanding of the mechanisms of tumorigenesis. Our analysis supports previous findings for the
deregulation of several pathways involved in cell cycle control and proliferation in both cancer types. A novel finding
of our analysis is a connection between ErbB4 and primary prostate cancer.
Citation: Edelman EJ, Guinney J, Chi JT, Febbo PG, Mukherjee S (2008) Modeling cancer progression via pathway dependencies. PLoS Comput Biol 4(2): e28. doi:10.1371/
journal.pcbi.0040028
Introduction
In the past several decades, many genes have been
discovered that govern important functions in the develop-
ment of a variety of different cancers. However, biological
insight from the list of genes is still limited and the
underlying mechanisms that occur in the cell during tumori-
genesis have not been well established. Numerous DNA
microarray expression datasets have been collected to proﬁle
genetic changes throughout tumor progression [1–6]. Tradi-
tionally, gene expression proﬁling has been used to identify
individual genes that become deregulated at distinct stages of
tumorigenesis. Such analyses have shown that tumor cells
have a great deal of heterogeneity as they progress through
the stages of cancer development [7]. The multitude of
differentially expressed genes can then be grouped together
by shared biological function to uncover mechanistic alter-
ations that may give rise to certain cancer states. This
approach has resulted in the understanding of some of the
genetic changes that occur during progression. However,
single gene based methods do not always provide clear and
accurate insight about the underlying biological processes
governing tumor development since these processes involve
sets of genes. Recently, gene set based methods have been
developed to investigate phenotypic changes at the pathway
level [8–11]. These methods provide an assessment of the
enrichment of a group of genes deﬁned a priori by some
biological commonality for certain phenotypes. The main
advantage of such methods over single gene based methods is
that they begin with biological knowledge and therefore
provide better functional or mechanistic insight into the
cause of the phenotypic differences.
In this paper we provide an integrative hierarchical
analysis of tumor progression which discovers a priori
deﬁned pathways that are relevant either throughout
progression or in particular steps in progression. Pathway
interaction networks are inferred for these relevant pathways
over the steps in progression. This is followed by the
reﬁnement of the relevant pathways to those genes most
differentially expressed over progression. The ﬁnal analysis
step is a gene interaction network inferred for these reﬁned
sets of genes. This analysis pipeline is applied to model
progression in prostate cancer and melanoma.
The machine learning and statistical ideas used in the
pipeline are regularized multi-task learning (RML) [12] and
the ideas of learning gradients [13–16] and inverse regression
[17,18]. The network inferences are based upon properties of
discrete Gauss-Markov graphs [19].
Results
We ﬁrst validate the accuracy of the annotation of the
pathway database used. We then describe in detail the
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cancer and melanoma.
Validation of Gene Sets
The database of gene sets we use in this paper is the
Molecular Signatures Database (MSigDB) [8]. This is a
collection of curated gene sets from online pathway data-
bases, publications in PubMed, and expert knowledge. Table
S1 contains the MSigDB of gene sets used in the following
analyses.
A key constraint in using a priori deﬁned gene sets and
pathways is the quality of the database of gene sets and the
accuracy of the annotation. Since the enrichment of gene sets
is fundamental to our models, we need to validate the
accuracy of these gene sets. Two points will be addressed in
our validation studies: the accuracy of gene sets annotated
according to known perturbations and a comparison of gene
sets deﬁned by experimental studies versus gene sets deﬁned
by expert knowledge. An afﬁrmative answer to the ﬁrst point
provides conﬁdence in the annotation and interpretations
made based on the annotations. A study of the second point
highlights the importance of the context of the gene set and
again provides information about interpreting results. An
afﬁrmative answer to this question allows for a uniform
analysis over both types of gene sets.
The validation of gene sets requires the knowledge of which
pathway gene sets are deregulated in which samples accord-
ing to known biology. This requirement is satisﬁed by studies
where a model system is genetically perturbed and a gene set
is deﬁned as genes that most differentially express under the
perturbation. Expression studies where the pathways driving
the phenotypic distinction are known also satisfy the above
requirement. Due to the difﬁculty in ﬁnding data satisfying
the above requirements for all the gene sets in our database
[8], we focus on a few gene sets which we can validate: the P53
pathway, the hypoxia pathway, and the RAS pathway. The
conclusion of our analysis will be that both experimental and
expert deﬁned gene sets seem to be accurately annotated and
gene sets deﬁned by expert knowledge may be applicable to
more general conditions.
P53 pathway. Our database of gene sets [8] contained 5 sets
deﬁning P53 pathways both from experimental studies and
from expert sources. We ﬁrst test whether these ﬁve gene sets
will be signiﬁcantly enriched in a dataset with a known P53
perturbation from the NCI-60 collection of cancer cell lines.
This dataset includes 12 normal samples and 50 samples with
a P53 mutation. Using GSEA, the normalized enrichment
score (NES), p-value, and false discovery rate (FDR) for the 5
P53 pathway gene sets along with the other gene sets in the
MSigDB were obtained. We found that the P53 pathway gene
sets were all signiﬁcantly enriched in the P53 wild type cells
(results summarized in Table 1). These results give conﬁdence
that the 5 P53 signatures, although from different sources, are
accurately representing the P53 pathway.
Further validation of the P53 pathway gene sets comes
from an indirect comparison based on P53 as a marker for
recurrence of breast cancer [20–22]. In [5], gene expression
proﬁles were obtained for 60 individuals with hormone
receptor-positive primary breast cancer treated with adju-
vant tamoxifen monotherapy. Of these individuals, 32
experienced tumor recurrence. All of the P53 pathway gene
sets except ‘‘P53 Up’’ differentiate the nonrecurrent from
recurrent breast cancer phenotypes and rank highly based on
their enrichment scores (see Table 2). The fact that ‘‘P53 Up’’
did not rank highly is not surprising as it is also the gene set
with the worst enrichment in the NCI-60 dataset. The ability
of the other four gene sets to differentiate P53 perturbations
and breast cancer phenotypes provides conﬁdence in using
these gene sets.
Hypoxia pathways. Our database of gene sets [8] contained
7 gene sets deﬁning hypoxia pathways (see Table 3) both from
experimental studies and from expert sources. Hypoxia
occurs when a cell experiences an oxygen deﬁciency. The
cell responds to the low oxygen environment by activating
certain hypoxia pathways which induce numerous adaptive
responses. Alternatively, cancer cells can genetically activate a
hypoxia response in the setting of normal oxygen levels to
Table 1. GSEA Results for the P53 Gene Sets in the Wild-Type/P53 Mutant Dataset
Rank Gene Set Source NES p-Value FDR
1 P53 Pathway BioCarta (http://www.biocarta.com)  2.38 0 0
2 Stress P53 Specific Up Amundson et al. [57]  2.33 0 0
3 P53 Hypoxia BioCarta  2.19 0 0
4 P53 Genes All Inga et al. [58]  2.1 0 0.01
10 P53 Up Kannan et al. [59]  1.73 0.02 0.20
The ranks are out of 220 gene sets that are enriched in the wild-type phenotype.
doi:10.1371/journal.pcbi.0040028.t001
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Author Summary
Cancer is a complex disease with many subtypes that differ
substantially with respect to their onset, progression, and response
to treatment. Better understanding of the etiology and mechanism
of cancer should help improve the diagnosis, prognosis, and
treatment of cancer that will kill more than half a million Americans
this year alone. Our study illustrates how integration of data over
multiple stages and modeling tumorigenesis at the level of
regulatory pathways or sets of genes provide robust and
interpretable novel hypotheses concerning root genetic causes
responsible for cancer initiation, progression, and invasion. Our
modeling approach is one of the first approaches that combines
multiple microarray datasets in a truly integrative framework that
promotes the interpretability of important factors or pathways in
one or more datasets. We apply this analysis of tumor progression to
both prostate cancer and melanoma to provide information that can
lead to the identification of novel biomarkers and give a basis for
how genetic disruptions serve to alter actions in specific cell types.
Modeling Cancer Progression via Pathwaysactivate new blood vessel formation and experience a growth
advantage. Recently, much work has been done to better
understand cellular responses to hypoxia conditions for
therapeutic targeting of cancer cells which have the ability
to adapt to these conditions and alter certain signaling
pathways to increase survival.
The enrichment of these 7 gene sets were examined in an
expression dataset which proﬁled 3 human astrocytes and 3
epithelial cells (HeLa cells) maintained under hypoxic
conditions and 3 human astrocytes and 3 HeLa cells
maintained under normal conditions [23]. GSEA was applied
to this dataset to examine the enrichment of the gene sets in
the database with respect to the 6 hypoxic and 6 normoxic
cells. The enrichment scores of the 7 hypoxia gene sets rank
highly out of the 528 gene sets tested from the MSigDB for
their ability to discriminate hypoxic and normoxic cells in
both cell lineages (astrocyte and epithelial cells) (see Table 3).
This provides further support for using gene sets deﬁned for
the same biological process from a variety of sources.
RAS pathway. The ﬁnal example illustrates the importance
of context in the pathway approach. The enrichment of three
RAS pathways gene sets were examined under two conditions
or datasets. The context of the ﬁrst dataset is very speciﬁc, an
animal model with mutated KRAS [24]. The second dataset is
much more heterogeneous, non-small cell lung cancers [25].
The three gene sets correspond to two experimentally
derived gene sets [24,26] and the RAS pathway from BioCarta
(http://www.biocarta.com). The RAS signature from BioCarta
is the most general with respect to context as it consists of
genes thought to biochemically interact with RAS and
proteins associated with RAS. The two experimentally
deﬁned gene sets are much more context speciﬁc. The ﬁrst
gene set corresponds to a pathway signature derived from
infecting human primary mammary epithelial cell cultures
with an adenovirus expressing activated HRAS [24]. The
second gene set is a pathway signature derived from a mouse
model with a KRAS mutation. In summary these two gene sets
annotate HRAS and KRAS deregulation. Although the three
sets all describe the RAS pathway, there are very few shared
genes between the sets, emphasizing the importance of
context when deﬁning gene sets. The HRAS gene set and
KRAS gene set share 8 genes and contain 237 and 58 unique
genes respectively. The RAS gene set deﬁned by BioCarta
contains 23 genes, sharing only 1 gene with the HRAS gene
set and having no genes in common with KRAS gene set.
The importance of the context in which a gene set was
deﬁned is demonstrated by testing the enrichment of the
HRAS gene set on a dataset with a KRAS mutation. The
HRAS gene set was split into the genes up-regulated and
down-regulated in response to RAS activity. In [24], micro-
arrays were collected from 31 cells with tumors caused by a
KRAS mutation and 19 normal cells. Using GSEA, the NES, p-
value, and FDR for the HRAS up-regulated and down-
regulated gene sets were obtained. The oncogenic pathways
of BCAT, E2F3, MYC, and SRC were also deﬁned in [24] and
were added to the analysis for enrichment comparisons.
Results are shown in Table 4. The experimental HRAS gene
set is narrowly deﬁned for genes perturbed by HRAS
activation and does not capture KRAS mutation speciﬁcity.
On the other hand, the RAS gene set deﬁned by BioCarta is
appropriate to use regardless of the speciﬁc RAS mutation as
it captures the interactions that the RAS protein can have
under different conditions.
The context of the RAS gene set does not have as much of
an impact on datasets that indirectly involve RAS perturba-
tions, even though the different RAS gene sets share a limited
Table 2. GSEA Results for the P53 Gene Sets in the Recurrent/Nonrecurrent Breast Cancer Dataset
Nonrecurrent/Recurrent Rank Gene Set NES p-Value FDR
Nonrecurrent 10 P53 Pathway  1.27 0.15 1
15 P53 Genes All  1.23 0.2 1
19 Stress P53 Specific Up  1.18 0.23 1
69 P53 Hypoxia  0.83 0.70 1
Recurrent 248 P53 Up 0.72 0.90 0.96
The ranks are out of 123 gene sets that are enriched in the nonrecurrent phenotype and 278 gene sets that are enriched in the recurrent phenotype.
doi:10.1371/journal.pcbi.0040028.t002
Table 3. GSEA Results for the Hypoxia Gene Sets in the Hypoxia/Normal Dataset
Rank Gene Set Source NES p-Value FDR
Enriched in hypoxic cells 3 Hypoxia Up Manalo et al. [60]  1.96 0.008 0.026
4 Hypoxia Review Harris [61]  1.95 0 0.027
6 Hypoxia Fibro Up Kim et al. [62]  1.84 0.004 0.088
9 Hypoxia Reg Up Leonard et al. [63]  1.73 0.02 0.191
10 HIF Pathway BioCarta  1.73 0.02 0.176
53 VEGF Pathway BioCarta  1.39 0.055 0.553
Enriched in normal cells 17 Hypoxia Down Manalo et al. [60] 1.48 0.167 0.596
The ranks are our of 323 gene sets which are enriched in the hypoxia phenotype and 205 gen sets which are enriched in the normal phenotype.
doi:10.10.1371/journal.pcbi.0040028.t003
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Modeling Cancer Progression via Pathwaysnumber of genes. Previous studies have shown that RAS
activation is linked with lung adenocarcinomas [27,28]. The
BioCarta RAS signature, the HRAS signature, and the KRAS
signature were tested for their diagnostic capabilities in
human lung cancer using a gene expression dataset with 45
adenocarcinoma lung cancer samples and 48 squamous lung
cancer samples [25]. Using ASSESS [9], enrichment scores
were calculated for each sample in the three RAS gene sets.
The class prediction accuracy based on enrichment score was
69.9% for the HRAS pathway, 75.3% for the KRAS pathway,
and 79.6% for the BioCarta RAS pathway.
These results give conﬁdence for the robustness of ASSESS
in allowing for the use of both literature and experimental
based gene sets when the dataset contains a more general
perturbation. However, if a dataset is built on a perturbation
of a speciﬁc proto-oncogene, enrichment will not be seen in a
gene set for a different proto-oncogene, even if these two
proto-oncogenes belong to the same family. Therefore,
knowing the context under which both the dataset and the
gene set were built is important for interpreting results of
enrichment analyses.
Modeling Framework for Cancer Progression
We ﬁrst state a summary of the framework we use to model
tumor progression. A detailed description of the steps in the
analysis and the methods from machine learning and
statistics used is provided in the methods section.
The analysis can be divided into three objectives that fall
into a natural hierarchical framework—an analysis at the
pathway level to identify important pathways and build
pathway networks, followed by a gene level analysis to reﬁne
relevant pathways and then infer a gene network for those
relevant pathways. The ﬁrst two objectives are at the pathway
level. The ﬁrst objective is to determine which pathways are
most relevant to progression over both transitions, normal
tissues to primary tumors fn a pg and primary tumors to
metastasizing tumors fp a mg, and those relevant to one
transition or the other. The second objective is to estimate
the interdependence of pathways relevant to each step of
tumor progression. This provides a pathway network for each
step of tumor progression. The third objective, the reﬁne-
ment of relevant pathways, is at the gene level. The reﬁne-
ment procedure removes genes in relevant pathway gene sets
that are not relevant to progression, resulting in a ‘‘reﬁned’’
gene set. A gene network for each reﬁned gene set can be
inferred by estimating the interdependence between genes.
In the following two subsections we apply this framework to
prostate cancer and melanoma.
Prostate Cancer Progression
The prostate cancer data [1] is a collection of cDNA
microarray expression measurements from 22 samples of
benign epithelium (b), 32 samples of primary prostate cancer
(p), and 17 samples of metastatic prostate cancer (m). The
progression is benign to prostate cancer (PCA) to metastasis,
fb a p a mg. We will follow the framework outlined in the
previous section for the analysis.
At each level of the analysis we use the six hallmarks of
cancer [29] to organize the analysis results. These hallmarks,
thought to be necessary for the development of cancer, were
deﬁned as self-sufﬁciency in growth signals, insensitivity to
anti-growth signals, evasion of apoptosis, limitless replicative
potential, sustained angiogenesis, and tissue invasion and
metastasis. It was hypothesized that tumors must acquire
alterations in each of these categories in order to evade the
multitude of anticancer defense mechanisms in the cell. We
use these hallmarks as categories to group gene sets found to
be relevant in our analysis. The gene sets are assigned to the
biological category most ﬁtting, although there are cases
where a gene set may fall into more than one category. In
addition, pathway gene set dependence graphs inferred will
illustrate the extent to which the hallmarks are interwoven.
Pathways gene sets corresponding to all six hallmarks were
found to be relevant.
Pathways relevant in prostate cancer progression. The ﬁrst
result of our analysis is a list of pathways and gene sets
relevant to progression in prostate cancer (see Table S2). In
addition, the analysis indicates in which stage of progression
a pathway is relevant: both steps in progression (Figure 1A),
the ﬁrst transition (Figure 1B), or the second transition
(Figure 1C). See Table 5 for the names and description of the
gene sets in Figure 1.
In the three cases, a p-value has been assigned to each of the
522 gene sets in the analysis. This p-value, calculated by
random class label permutations (see methods section),
assumes a null distribution with exchangeable labels. For
each of the three stages in progression, we chose those gene
sets with p   0.05 as relevant. This resulted in 29 gene sets
relevant to overall progression, 17 gene sets relevant in early
progression, and 22 gene sets relevant in late progression.
These relevant gene sets will be discussed in the remainder of
this section.
Pathway gene sets known to be involved in self-sufﬁciency
in growth signals were found to be relevant over all stages of
progression. In the list of signiﬁcant gene sets relevant
through both stage transitions several cell cycle gene sets are
present. These gene sets correspond to general function
required for the cell cycle to run normally. For instance, the
cell cycle checkpoint gene set deﬁned by Gene Ontology is
found to be relevant. This gene set is comprised of genes
involved in checkpoints for the spindle formation, DNA
integrity, G2/M transition, G1/S transition, cell size, and
meiotic recombination. The relevance of this gene set gives
Table 4. GSEA Results for the Oncogenic Gene Sets Defined [24]
and BioCarta in the KRAS Mutant/Normal Dataset
Gene Set NES p-Value FDR
Enriched in tumor RAS Up BioCarta 1.51 0 0.05
SRC Down 1.41 0.09 0.32
MYC Up 1.25 0.15 0.35
SRC Up 1.25 0.15 0.21
HRAS Up 1.12 0.26 0.49
E2F3 Up 1.12 0.25 0.33
BCAT Up 0.81 0.74 0.80
Enriched in normal RAS Down BioCarta  1.51 0.12 0.06
E2F3 Down  1.29 0.10 0.49
HRAS Down  1.18 0.19 0.52
BCAT Down  1.14 0.29 0.32
MYC Down  0.99 0.55 0.52
The BioCarta gene sets are named ‘‘RAS Up BioCarta’’ and ‘‘RAS Down BioCarta.’’ The
remaining gene sets are experimentally derived in [24]
doi:10.1371/journal.pcbi.0040028.t004
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Modeling Cancer Progression via Pathwaysan idea of the general perturbations intrinsic to the tumor
cell. However, a more detailed understanding of the
mechanism for tumor progression and proliferation can be
gained by studying relevant gene sets corresponding to
particular pathways. Both the ErbB4 pathway and EGF
receptor signaling pathway are found to be enriched in all
stages of tumor progression. These two pathways are related.
ErbB4 (or HER4) is a member of the EGF receptor family and
is involved in growth signaling. Therefore, it is reasonable to
hypothesize that one of the underlying mechanisms in self-
sufﬁciency in growth signals may be the deregulation of the
EGF cell surface receptor ErbB4, which results in the
increased transduction of growth stimulatory signals into
the cell. Further evidence of the importance of EGF signaling
is seen with the ERK pathway. Like the EGF pathway, the ERK
pathway is involved in RAS signaling and thereby increases
proliferation and development [30]. The behavior of the
Hormonal Function gene set is of great interest. The
enrichment of this gene set decreased in the prostate cancer
to metastatic transition. This trend has been documented in
prostate cancer where during progression the tumors become
androgen independent resulting in decreased androgen
production in the cell [31].
Pathways corresponding to insensitivity to anti-growth
signals were also found to be relevant in our analysis.
Throughout progression, the PTEN pathway was shown to
have decreasing enrichment and the PTDINS pathway was
shown to be up-regulated. These two pathways are closely
linked. PTDINS signals PTEN which is a tumor suppressor
gene that is often mutated in prostate cancer. PTEN down-
regulation, as well as PTDINS activation, leads to the
activation of the AKT pathway and anti-apoptotic activity
[31].
Pathways corresponding to the evasion of apoptosis were
found to be relevant at all stages of prostate progression. The
TNF and FAS Network gene set and the ROS gene set were
found to be signiﬁcant. FAS is a member of the TNF receptor
family normally involved in cell death. The down-regulation
of this pathway seen in late progression can be implicated
with anti-apoptotic activity. ROS was shown to be down-
regulated throughout progression. ROS generation in mito-
chondria activates caspase-3 and leads to a pro-apoptotic
activation cycle [32]. The deregulation of ROS therefore may
be an anti-apoptosis mechanism important in prostate
cancer.
Although pathways corresponding to limitless growth were
not as prominent as the ﬁrst three hallmarks, we do see one of
t h ec l a s s i cm a r k e r so ft h i sc h a r a c t e r i s t i c ,H T E R Tu p -
regulation. The length of telomeres indicate the number of
cell generations elapsed. With each generation, telomeres lose
50–100 base pairs and when the telomeres get to a critical
length, the cell undergoes senescence [33]. The gene set for
Figure 1. Pathways Relevant to Progression
The top figure displays enrichment scores of the two gene sets with the smallest p-values for relevance throughout progression fb a p a mg based on
RML. The middle figure displays two gene sets with the smallest p-values for relevance to the early transition fb a pg based on RML. The bottom figure
displays the two gene sets with the smallest p-values for relevance to the late transition fp a mg based on RML. The enrichment scores are plotted
from both transitions, fb a pg and fp a mg. Each column represents a sample. As such, the samples from the primary stage are plotted twice since
they are used in the enrichment analysis of both transitions. For each transition, the samples within the primary stage are plotted in the same order. See
Table 5 for full pathway names.
doi:10.1371/journal.pcbi.0040028.g001
Table 5. Gene Set Names for the Gene Set IDs in Figure 1
Set ID Gene Set Name Source
TRANS Transport Brentani et al. [64]
EGF EGF receptor signaling pathway BioCarta
GHD MAP00361 gamma hexacholrocyclohexane degradation GenMAPP (http://www.genmapp.org)
STER MAP00100 sterol biosynthesis GenMAPP
HORM Hormonal functions Brentani et al. [64]
GLY GLYCOL Broad Institute (Table S1)
doi:10.1371/journal.pcbi.0040028.t005
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Modeling Cancer Progression via Pathwaysthe telomerase enzyme HTERT is shown to be up-regulated in
late progression. HTERT over-expression maintains telomere
length, thereby enabling unlimited replicative potential [34].
The analysis does not reveal speciﬁc angiogenesis gene sets
relevant to progression. Previous research has found hypoxia
signatures associated with poor prognosis of many cancer
types including breast and ovarian, yet not prostate cancer
[35]. The analysis does however indicate many metabolic
pathways, giving evidence for the cell’s need for additional
nutrients as the cell grows and proliferates.
It has been previously documented that the capacity for
invasion is a multi-step process and the process of acquiring
the numerous needed perturbations often begins early in the
disease process [36]. The results support this ﬁnding,
indicating several pathways associated with invasion to be
relevant early in progression. For example, the mCalpain
pathway was found to be up-regulated in the benign to PCA
transition. This pathway is associated with invasion through
the regulation of integrin-mediated cell migration [37].
An interesting observation we ﬁnd is that many gene sets
involved in energy production rank highly in the analysis.
There is a glycolysis pathway signiﬁcant to the overall
progression and two additional glycolysis pathways relevant
to the late transition. In the early transition, the oxidative
phosphorylation gene set is also up-regulated. The up-
regulation of each of these gene sets describes the cell’s
continual need for energy as it undergoes additional
replications and eventually invasion and metastasis.
Preliminary validation of pathways relevant in prostate
cancer progression. We carried out two analyses to validate
our results from the above section. The ﬁrst validation metric
was the leave-one-out cross-validation error. The accuracy
was 96.11%, giving conﬁdence to the robustness of the RML
model.
We next performed a preliminary validation of the path-
way gene sets found to be relevant in our analysis by
examining their enrichment in an independent prostate
cancer dataset [38]. This dataset consisted of local and
metastatic prostate cancer samples. The enrichment of the
same 522 gene sets was computed using GSEA with respect to
the local versus metastatic class labels. The validation metric
was the overlap in the top 20 gene sets from the ranked list
obtained from the NES from GSEA to the top 20 gene sets
from the ranked list of gene sets found to be most relevant in
the prostate cancer to metastatic transition. There were 8
gene sets in the overlap corresponding to a p-value of 9.2 3
10
 8 using the hypergeometric distribution. Included in this
overlap are several cell cycle control and energy production
gene sets. This result gives conﬁdence that the gene sets
identiﬁed in our analysis are indeed signiﬁcant for disease
progression. We again see the utility of using gene sets instead
of single genes as a similar analysis done with single genes
resulted in no overlap.
Pathway dependency structure in prostate cancer progres-
sion. Given inferences of pathways relevant to each step of
tumor progression, the second objective is to understand how
these pathways interact at speciﬁc stages of progression. The
goal here is to infer a pathway interaction network for each
stage of progression. This information will provide knowl-
edge on the relationship between gene sets at a higher level—
how certain pathways relate, interact, and inﬂuence each
other with respect to the phenotype being studied, thereby
creating a dependency structure of the pathways. The
relationships are visualized by an undirected graphical model.
We do not claim nor model causality in these graphical
models, however we believe that causative relationships may
be suggested that can be further experimentally tested.
We ﬁrst look at three dependency relationships of interest.
As previously discussed, the PTEN and PTDINS pathways are
known to be closely associated. This is supported in the
analysis by the dependency relationship between the two
pathways. PTDINS is the 15th ranked pathway out of 522
based on the covariance with the PTEN pathway throughout
progression. Likewise, the IGF1R and ERK pathways are
known to be linked through their common association with
the RAS pathway. We ﬁnd support for their association as the
ERK pathway ranks 9th based on the covariance with the
IGF1R pathway during overall progression. Finally, PTDINS
ranks 32nd based on the covariance with IFG1R, recapitulat-
ing the known relationship between these two pathways.
These ﬁndings support the ability of our analysis to identify
pathways that are closely associated.
As previously discussed, p-values were calculated for each
of the 522 gene sets in the analysis. We chose the ten gene sets
Figure 2. Pathway Association Graphs
An association graph of (A) the top 10 gene sets in the fb a pg transition and (B) the gene sets with p , 0.05 for the fb a pg transition. The red lines
indicate a positive dependence while the blue lines indicate a negative dependence. Distances between gene sets reflect the strength of dependencies.
See Table S2 for full pathway names.
doi:10.1371/journal.pcbi.0040028.g002
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Modeling Cancer Progression via Pathwayswith the lowest p-values in the benign to prostate cancer step
in progression. The dependency structure of these gene sets
are displayed in Figure 2A. Although these ten gene sets are
all signiﬁcant in differentiating the benign and PCA samples,
the dependency structure shows that some may be more
inﬂuential than others. For example, there is a group of 7
gene sets which cluster closely together, indicating that the
deregulation of these genes sets play a key role in the
phenotypic change from benign to PCA. We call these the
core gene sets for the early step in progression. Gene sets with
fewer connections are also important in phenotypic deter-
mination, however, the enrichment of these gene sets over all
of the samples differ slightly from the core group. The
assumption here is that one, or a few, of the gene sets in the
core group are inﬂuencing the expression of the other gene
sets, both in the core group and on the outside connections.
The Sterol Biosynthesis and FA (Fanconi anemia) gene sets
are both highly connected to the other gene sets. These are
good candidates for pathways which are strongly inﬂuencing
the expression pattern of other pathways.
Further information on gene set interactions can be gained
by increasing the number of gene sets examined and
displaying the dependence structure. For example those gene
sets with p   0.05 are shown in Figure 2B. Most of the gene
sets discussed previously were relevant throughout progres-
sion and therefore do not appear in this network of sets
describing the early transition. The few gene sets discussed
that are relevant in the early transition do indeed appear in
the network, such as the ERK pathway and Hormonal
Function gene set. The gene sets which clustered tightly in
Figure 2A still cluster tightly in the middle of Figure 2B.
However, several additional gene sets are shown to have
strong dependencies with these gene sets as well. The
additional gene sets are important in the phenotypic
transition but have slightly different enrichment patterns as
the top 10 gene sets. Aside from the Sterol Biosynthesis and
FA gene sets, the Hormonal Functions gene set has the largest
number of connections, indicating that it may also be
governing expression patterns. It is further apparent that
gene sets from each of the hallmarks of cancer interact with
one another. Therefore, although each hallmark represents a
unique characteristic, they are not separate entities but
rather inﬂuence one another.
Reﬁnement of pathways in prostate cancer progression.
The pathway level analysis provides us with inferences of
which pathways are relevant over the two steps of prostate
cancer progression as well as the interaction between path-
ways. The next level of analysis is the reﬁnement at the gene
level. The pathways found to be relevant in each of the steps
of progression are reﬁned using procedures described in the
methods section. The HRAS/KRAS gene set validation
example provides an argument for reﬁnement. Pathways
available are not always in the right context for a speciﬁc
dataset of interest. The reﬁnement procedure adapts the gene
set to the context of the dataset. Adding this gene set to the
database of gene sets increases the diversity of the collected
gene sets. In addition, a gene network modeling the
interdependence of the genes in the reﬁned gene set is
inferred.
The reﬁnement procedure consists of culling the pathway
gene set to a ‘‘reﬁned’’ set corresponding to the genes in the
set most relevant to the transition. We applied the reﬁnement
procedure to the top 3 pathway gene sets in Table S2 based
on p-values in the PCA to metastatic transition as well as 2
pathway gene sets with varying ranks. The reﬁned gene sets
were added to our database of gene sets and are listed in
Table S3.
After adding the reﬁned gene sets to our gene set database,
the analysis was repeated to examine whether the new gene
sets better differentiate phenotype as compared to the
original sets. In all the gene sets analyzed, the reﬁned gene
sets rank higher than the original as expected since the
reﬁned gene sets represent the subset of genes most strongly
correlated with phenotype (see Table 6).
The reﬁned gene sets were then analyzed on an independ-
ent prostate cancer dataset [38]. Using GSEA, we again see
improvement in the rankings of the NES of each of the 5
reﬁned gene sets over the original sets.
We also applied the reﬁnement procedure to the ERK
pathway gene set in the benign to PCA step in progression.
Figure 3A and 3B displays all of the genes in the ERK pathway
as deﬁned in BioCarta and visualizes the pathway network.
The difference between the plots is the threshold value below
which dependencies are not displayed. The threshold is
higher in Figure 3A than 3B so only the strongest interactions
are displayed here. In Figure 3A and 3B there are 7 genes that
all covary strongly with one another. These 7 genes are
deﬁned as the reﬁned set. MYC is shown to have a strong
relationship with the most genes in the gene set, being
strongly dependent with respect to 8 genes. In addition to
learning which genes are active in the pathway, Figure 3A
displays numerous genes which are not relevant in this
context. We conclude that the reﬁned set of 7 genes, and in
particular MYC, play an essential role in the ERK pathway
deregulation seen in early prostate cancer progression.
Novel ﬁndings. In addition to recapitulating previous
ﬁndings for prostate cancer progression, new hypotheses
have emerged out of our study. One interesting observation
from the analysis is the relevance of ErbB4 in the early
transition, suggesting the hypothesis that the ErbB4 pathway
becomes deregulated in PCA individuals. The importance of
EGF receptors have been documented in several cancer types,
such as stomach, brain, and breast tumors [39,40]. HER2 has
been implicated to be over-expressed in prostate cancer
samples and thought perhaps to be related to the develop-
Table 6. Rankings of Original and Refined Gene Sets for the PCA
to Metastatic State Transition Based on RML
Prostate fp a mg Gene Sets Size Rank
CR HORMONAL FUNCTIONS, original 12 6
CR HORMONAL FUNCTIONS, refined 4 3
GLYCOL, original 22 12
GLYCOL, refined 6 9
TRANSPORT OF VESICLES, original 26 18
TRANSPORT OF VESICLES, refined 6 5
ptdinsPathway, original 22 51
ptdinsPathway, refined 5 25
gcrPathway, original 19 125
gcrPathway, refined 5 39
Rankings are of our of 527 gene sets (522 original gene sets plus 5 refined sets).
doi:10.1371/journal.pcbi.0040028.t006
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little is known about a connection between ErbB4/HER4 and
prostate cancer. Our analysis can motivate further research
on deﬁning the role of ErbB4/HER4 and prostate cancers.
Another interesting ﬁnding is the importance of the FA
gene set in the early transition. The FA protein complex is
known to associate with BRAC1 and BRCA2 and be involved
in cell repair machinery [42,43]. Alterations in FA protein
complex has been linked to several types of cancer including
breast, brain, lung, and oral cancer [42,44].
Melanoma Progression
We will further test our analysis on a melanoma tumor
progression expression dataset. Genome-wide expression at
different stages of melanoma development is available in [2].
Samples were categorized as normal (n), primary (p), or
metastatic (m), with 4 individuals per group. The progression
is normal to primary to metastasis, fn a p a mg. We follow
the same hierarchical framework, analyzing relevant path-
ways, pathway networks, and ﬁnally gene networks.
Pathways relevant in melanoma progression. The enrich-
ment of gene sets with the lowest p-values for relevance
throughout disease progression are displayed in Figure 4A,
those most relevant in the transition from normal to primary
are displayed in Figure 4B, and those for the transition from
primary to metastatic are displayed in Figure 4C. See Table
S4 for the full listing of pathways relevant with a p   0.05. The
top two ranked gene sets for each transition are listed in
Table 7.
The results provide an understanding at the pathway level
of the deregulation occurring in a developing melanoma cell
to achieve the capacity for self-sufﬁciency of growth. Two well
documented factors inﬂuencing self-sufﬁciency of growth are
relevant to overall progression. The oncogene E2F is
continuously over-expressed, increasing cell proliferation.
Additionally, the AKT pathway is up-regulated which
Figure 3. ERK Pathway Gene Association Graphs
An association graph of the ERK pathway gene set with (A) a strong threshold on gene dependencies and (B) a weak threshold on gene dependencies.
The red lines indicate a positive dependence while the blue lines indicate a negative dependence. Distances between genes reflect the strength of
dependence between genes.
doi:10.1371/journal.pcbi.0040028.g003
Figure 4. Enrichment Scores of the Two Highest Ranked Gene Sets from RML
(A) fn a p a mg. (B) fn a pg. (C) fp a mg. See Figure 1 for further details and Table 7 for full pathway names.
doi:10.1371/journal.pcbi.0040028.g004
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pathway is one of the effector pathways of RAS and can be
activated by PTDINS over-expression, which we also see as
relevant throughout melanoma progression. Our analysis
suggests that the Sprouty pathway, which normally blocks
EGF signaling [45] and prevents the activation of the RAS
signaling pathway [46] is down-regulated.
The second hallmark of cancer, insensitivity to anti-growth
signals, is also seen in melanoma. In the early transition, the
CDK5 pathway is down-regulated. This alteration has been
documented to lead to the activation of MEK1, a member of
the MAP Kinase RAS effector pathway, and thereby to
increased cell growth [30].
Several mechanisms for the escape from apoptosis are seen
to be important in progression. Repression of apoptosis
occurs through D4-GDI and IGF1R pathway over-expression
and P53 and FA pathway under-expression. Decreased
expression of the tumor suppressor P53 pathway throughout
progression brings about unregulated continuation through
the cell cycle, even when DNA damage is present [47]. The FA
pathway has been implicated in several cancer types [42,44]
but not yet reported in melanoma. Finally, the IGF1R
pathway is found to be relevant to the late transition where
the over-expression increases anti-apoptotic activity.
During melanoma progression, mechanisms involved in the
defense against limitless replicative potential become deregu-
lated. The HTERT gene set is shown to be up-regulated in
early progression. HTERT over-expression maintains telo-
mere length, thereby enabling unlimited replicative potential
[34]. The fact that this alteration is seen in early disease
development points to the importance of acquiring the
capability for limitless growth in order to proceed into a
neoplasia in addition to deregulation in other growth
mechanisms.
Two important gene sets describing angiogenesis are seen
during melanoma progression. The HIF pathway gene set
shows over-expression throughout progression, indicating
the neoplasia’s continual increasing requirement for oxygen
and nutrients. HIF-1 is activated during hypoxia leading to
the induction of a network of genes involved in angiogenesis
and glucose metabolism [48]. We again see the need for an
increase in oxygen early in the disease by the Angiogenesis
gene set that is found to be up-regulated at the early
transition.
The ﬁnal hallmark of cancer, invasion and metastasis, is
acquired in melanoma progression. Cells gain the capacity for
metastasis by alterations in proteins involved in cell-to-cell
adhesion and cell-to-environment interactions [49]. We see
proteins of this class to be altered through the deregulation
of the Cytoskeleton gene set. The MTA3 pathway is down-
regulated in the early transition. Decreased expression of
MTA3 has been associated with ER-negative breast tumors.
This down-regulation leads to the halt of E-cadherin
production. E-cadherin is involved in coupling adjacent cells
and transmitting anti-growth signals and is a widely observed
alteration in cancers with invasion capacities [50].
Preliminary validation of pathways relevant in melanoma
progression. We carried out two analyses to validate our
results from the above section. First, classiﬁcation was applied
in the leave-one-out setting (see methods). There were no
errors in class prediction, giving conﬁdence to the robustness
of the RML model.
The second analysis involved an independent melanoma
progression dataset [51]. This dataset consists of 9 samples of
benign nevis, 6 samples of primary melanoma, and 19 samples
of metastatic melanoma. The regression analysis was rerun on
this dataset and several of the signiﬁcant pathways from the
ﬁrst analysis were again found to be signiﬁcant. In both
analyses we found the down-regulation of the P53 pathway
gene set throughout progression and the over-expression of
the D4-GDI pathway and the HTERT gene sets at various
stages in progression. The overlap of relevant gene sets from
the two datasets [2,51] however was not found to be
signiﬁcant (p ¼ 0.28). This may be attributed to the small
sample size in the ﬁrst dataset [2]. To further explore this
issue, we randomly split the second dataset [51]. The
regression analysis was run on the two resulting datasets
independently. For each, we obtained a list of gene sets with p
  0.05 for overall progression. Using the hypergeometric
distribution, the overlap of the two lists was found to be
signiﬁcant, p ¼ 0.018. This result gives conﬁdence against
overﬁtting and that the gene sets identiﬁed in the analysis are
indeed signiﬁcant.
Pathway dependency structure in melanoma progression.
The dependency structure of the 10 pathways with the lowest
p-values in the normal to primary transition is shown in
Figure 5A. Although we do not have direct validation about
the level of interaction of these pathways, we have conﬁdence
they are all signiﬁcant in the fb a pg transition from the RML
analysis and their strong resulting p-values. We gain further
conﬁdence in their dependency structure through docu-
mented ﬁndings of similar interactions. As in the prostate
cancer progression example, the Sterol Biosynthesis gene set
is highly connected. Tumor cells have long been documented
to have deﬁciencies in sterol synthesis. One component of the
Sterol Biosynthesis gene set is the mevalonate pathway, which
is a key intermediate in sterol production. In [52], it was
found that tumor cells cannot synthesize mevalonate, but can
obtain it from the host and then continue along in the sterol
pathway. The dependency structure shows that the Sterol
Biosynthesis gene set has a strong positive interdependence
with the Fatty Acid Synthesis, Cyanoamino Acid Metabolism,
and Gamma Hexachlorocyclohexane Degradation gene sets.
The interdependence of these three gene sets with the Sterol
Biosynthesis gene set rank 14th, 19th, and 3rd, respectively,
out of the 523 pathways in the database. All of these gene sets
may be closely tied to the inability of a tumor to synthesize
certain metabolites and its increasing need for these
metabolites as it grows and develops. Figure 5B displays the
Table 7. Gene Set Names for the Gene Set IDs in Figure 4
Set ID Gene Set Name Source
HIF Hif pathway BioCarta
AKT Akt pathway BioCarta




DREAM Dream pathway BioCarta
IGF1R Igf1r pathway BioCarta
doi:10.1371/journal.pcbi.0040028.t007
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Modeling Cancer Progression via Pathwaysgene set dependency network for gene sets with p   0.05. The
top original top 10 gene sets cluster tightly, recapitulating
their close relationships.
Discussion
The major innovation presented in this paper is the use of
gene sets in modeling tumor progression rather than single
genes. Previous research in tumor progression has studied
single genes that can be used as markers of certain stages
[2,3]. While it is important to identify these individual genes,
a broader understanding of the biological processes occur-
ring during progression has been missing. Recent research in
prostate cancer progression has taken a step closer to gaining
insight into biologically related gene sets implicated through-
out disease using the Molecular Concept Map [1]. This
method identiﬁes cellular functions that may be relevant
based on common characteristics in the individual genes
found to be differentially expressed. An analysis of breast and
colorectal cancer was performed by [53], grouping genes
using similar gene set databases, such as Gene Ontology and
the KEGG Pathway Database. Unlike these analyses, we start
in the space of gene sets rather than individual genes. We
have introduced a novel analysis pipeline that discovers a
priori deﬁned gene sets relevant at different stages of the
disease. In addition, an interaction network of these relevant
gene sets is inferred. This is followed by reﬁnement of the
relevant pathways and gene sets to include only the genes
most relevant to progression. A gene interaction network is
inferred for these reﬁned gene sets. This approach provides a
more accurate and descriptive understanding of pathway
deregulation by identifying speciﬁc pathway gene sets whose
expression becomes altered along with phenotypic changes.
Since the method requires accurately deﬁned gene sets, we
ﬁrst sought to validate the gene sets used in the analyses. P53,
hypoxia, and RAS pathways have been deﬁned by multiple
sources, both in literature and experimental settings. For
each, we took data with a speciﬁc perturbation for that
pathway and calculated pathway enrichment. Results sug-
gested that the gene sets are appropriate for use with careful
attention to context. Context of both the dataset and gene set
is important in enrichment analyses. We ﬁnd this in the
HRAS/KRAS example. Gene sets deﬁned on one dataset may
not be applicable for enrichment analyses when the context
of the dataset changes. As such, careful attention should be
paid for application of gene sets deﬁned on one data set to a
different context.
Our results largely agreed with ﬁndings in previous studies
but also provide some novel biological insights into tumor
progression. We discovered gene sets which become deregu-
lated at certain stages and throughout progression. Common
themes in the results presented in this paper and in [1]
include an increased activity in the cell cycle, an increase of
energy requirements, and an initial increase followed by a
decrease in hormonal levels. The technique applied in [1]
gave concepts which were relevant at certain stages of
prostate cancer progression such as the concept of ‘‘cell
cycle,’’ shown to have increased activity throughout pro-
gression. Our analysis takes this result a step further by
discovering the speciﬁc pathways responsible for the in-
creased activity, for example the ERK pathway in early
progression. This provides better mechanistic insight into the
process of proliferation during tumorigenesis.
In [2], individual genes were identiﬁed that were speciﬁc to
create genetic proﬁles for different stages of melanoma.
Although it is important to identify such markers that can
differentiate stages, they do not provide an understanding of
Figure 5. Pathway Association Graphs
An association graph of (A) the top 10 gene sets in the fn a pg transition and (B) the gene sets with p , 0.05 for the fn a pg transition. The red lines
indicate a positive dependence while the blue lines indicate a negative dependence. Distances between gene sets reflect the strength of dependencies.
See Table S4 for full pathway names.
doi:10.1371/journal.pcbi.0040028.g005
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Modeling Cancer Progression via Pathwaysthe underlying mechanisms that drive progression. [2] ﬁnds
that genes involved in cell cycle regulation and proliferation
are of utmost importance during melanoma development.
Our method discovers several mechanisms underlying cell
cycle regulation and proliferation that become deregulated
such as the AKT and P53 pathways.
Studies have also been performed using comparative
genomic hybridization (CGH) to associate DNA copy number
aberrations with genetic progression [54,55]. We do not
present such an analysis at this time; however, our analysis
can be applied in this setting by using chromosomal regions
as gene sets.
By transforming expression datasets into the space of
enrichment scores of gene sets, we have extended previous
research to gain insight into disease processes at the pathway
level. We are able to study simultaneously the progression
over multiple steps in tumor progression and provide
pathway interaction networks of pathways relevant to these
multiple steps.
Methods
We ﬁrst present an overview of the steps in the analysis,
summarized in the data analysis algorithm below. We then proceed
to explain in detail the algorithms and statistical models involved in
each step of the analysis pipeline.
Analysis pipeline. The same data analysis algorithm or pipeline was
followed for both the prostate cancer and melanoma examples.
The following are the analysis steps:
1. Stratify data: The expression data is stratiﬁed into T datasets
corresponding to stages of progression. For example, if the
progression is fb a p a mg then there are two steps, T ¼ 2. The
ﬁrst dataset D1 consists of samples of class b and p and the second
dataset D2 consists of samples of class p and m;
2. Map to summary statistics: The stratiﬁed data Dt is mapped into a
representation with respect to sets of genes or pathways, C, deﬁned a
priori. Pathways in this setting are genes putatively thought to co-
express. Given the stratiﬁed data Dt and a pathway database C, the
summary statistic provides a measurement of the enrichment of each
sample in Dt with respect to each pathway in the database. If the
dataset Dt has p genes and n samples and there are m pathways in the
database then the result of the summary statistic is a new dataset, St,o f
the enrichment of the m pathways over the n samples.
3. Find pathways relevant to progression: The RML algorithm
was applied to the mapped data fStg
T
t¼1. The output of the
RML algorithm are a set of vectors fw0;wtg
T
t¼1 where the
elements of w0 correspond to the relevance of a pathway over
all stages of progression and the elements of wt correspond to the
relevance of a pathway with respect to the t-th step in progression. A
permutation procedure was performed to obtain p-values for each
gene set in respect to each step in progression;
4. Leave-one-out cross-validation: Given data set fStg
T
t¼1 of
enrichment scores, apply RML to training data in a leave-one-out
setting. This results in an unbiased estimate of the error rate on the
prediction of class labels.
5. Construct pathway association graphs: For the pathways found
to be relevant over the T stages of progression construct a pathway
association graph fAtg
T
t¼1. Each ij-th element of A
t indicates the
dependence between pathways i and j conditioned on all other
pathways and the relevance in modeling transition t.
6. Reﬁne relevant gene sets: The pathways Gt found to be relevant
for the t-th step in progression are reﬁned since not all genes in the
pathway are relevant in modeling transition t. This results in a set of
reﬁned gene sets C
R and g¼jC
R j is the number of reﬁned gene sets.
7. Construct gene association graphs for reﬁned pathways: For




k¼1 construct a gene associa-
tion graph A ˜k where the ij-th element of A ˜k indicates the depen-
dence between genes i and j conditioned on all other genes ck and the
relevance in modeling transition t.
Stratiﬁcation and mapping. The ﬁrst two steps in the analysis
pipeline are stratifying the data and mapping the data into a repre-
sentation based on pathways. The data can be represented as a set of
pairs D¼fxi;yig
n
i¼1 with xi 2
p the expression over p genes and yi is the
stage of the patient. Assume that there are three stages y 2f b, p, mg
with n1,n 2,n 3 samples in each stage and the progression is fb a p a
mg. There are two steps in this progression, T ¼ 2.
We ﬁrst stratify the data with respect to these two steps. The ﬁrst
dataset D1 ¼f x1;y1g
n1þn2
i¼1 consists of the n1 samples corresponding to
stage b followed by the n2 samples corresponding to stage p with the
label of the ﬁrst n1 samples labeled as 0 (less serious) and the
remaining n2 labeled as 1 (more serious). The second dataset D2 is
constructed similarly with samples corresponding to stages p and m.
The ﬁrst n2 samples are labeled as 0 (less serious) and the remaining
n3 labeled as 1 (more serious) in this dataset.
Each dataset Dt is then mapped into a representation with respect
to sets of genes or pathways. This is done using the pathway
annotation tool ASSESS [9] that assays pathway variation in
individuals. Given phenotypic or label data Yn ¼f y1,...,y ng,
expression data Xn¼fx1,...,x ng and gene sets C¼fc1,..., cmg deﬁned
a priori ASSESS [9] provides the summary statistic Sn ¼ S(Xn, Yn, Cg.
The summary statistic Sn is a matrix with n columns corresponding to
samples and m rows corresponding to gene sets with each element Sij
as the enrichment of gene expression differences in the j-th sample
with respect to phenotype for genes in the i-th gene set. The
application of ASSESS to the stratiﬁed datasets D1, D2 results in two
datasets S1,S 2. The gene sets used in our analysis were those
annotated in the MSigDB [8].
Finding pathways relevant to progression. The central statistical
idea used in ﬁnding pathways relevant to progression is called multi-
task learning [12] in the machine learning literature and hierarchical
modeling with mixed effects in the statistics literature. We restrict
ourselves in this paper to linear models and classiﬁcation. The basic
idea is that we have T classiﬁcation problems in our case assigning a
sample xi to labels 0 (less serious) or 1 (more serious). We assume that
the classiﬁcation tasks are related so the conditional distributions of
the phenotype given the summary statistics lt(Y j S) are also related.
The tasks in our case are the different steps in tumor progression and
the data over all tasks is S¼S1,...,ST where Sj¼f(y1j, s1j),...,(ynj, Snj)g and
nj is the number of samples in the j-th task. We assume the generalized
linear model
yit ¼ g½sitðwo þ vtÞþb ¼g½sit   wt þ b ;
where g is a link function which for the SVM case is (yit sit   wt b)þ,
wt¼w0þvt,yit isthei-thsamplein taskt, sitare thesummarystatisticsof
the i-th sample in task t, w0 is the baseline term over all tasks, vt are the
task speciﬁc corrections, and b is an offset. The vectors wt correspond
to the linear model for each task.
We used the RML framework developed in multitask to estimate












where (u)þ¼min(u, 0) is the hinge loss, f(sit)¼sit  (woþvt)þb, k1 and k2
are positive regularization parameters that trade-off between ﬁtting
the data and the smoothness or robustness of the estimates. In this
paper we set k1¼1 and k2¼2,000, as to not over assume dependency
between tasks.
Given the vectors wt we select gene sets corresponding to
coordinates of the vectors with p   0.05 to ﬁnd pathways relevant
to the t-th step in progression, see [56] for details.
Permutation procedure. RML was repeated with 1,000 class label









p¼1 . The p-value for each gene set in wt was obtained




p¼1 . Gene sets relevant to the
t-th step in progression, Gt, are those corresponding to elements of wt
with p   0.05.
Classiﬁcation in the leave-one-out setting. We applied the leave-
one-out procedure for classiﬁcation. The dataset fStg
T
t¼1 is split into
si (the i-th data sample) and S
\i (the data without the i-th sample). RML
is applied to the training set, S
\i to build a classiﬁer based on
fw0;wtg
T
t¼1 which is applied to si to obtain a prediction ^ yi. Prediction
accuracy is computed by applying the leave-one-out procedure to all
samples in the dataset.
Association graphs and reﬁnement of gene sets. The central
statistical idea used in constructing association graphs as well as
reﬁning gene sets is learning gradients [13–16] and inverse regression
[17,18]. These ideas apply to linear and nonlinear models but we
restrict ourselves to the linear setting since we only use linear models
in this paper. We ﬁrst formulate the statistical ideas and then
describe how this is applied in our application.
Learning gradients, inverse regression, and graphical models: The idea of
inverse regression [17,18] is given the explanatory or input variables
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Modeling Cancer Progression via PathwaysX and the output or response variable Y to study XjY and more
speciﬁcally XXjY ¼ cov(X j Y):
1. The i-th diagonal element of this covariance matrix is a measure
of the relevance of the i-th variable with respect to changes in the
label or output variable;
2. The j-th off-diagonal element is a measure of the covariation
between variable i and j with respect to changes in the label.
Estimating the inverse regression can be technically problematic if
the covariance matrix is degenerate.
The idea of learning gradients addresses this technical problem.
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;





@x ji. In [16] the following relation between the GOP






where RX ¼ cov(X) for the inputs, and r2
Y ¼ var (Y) for the outputs.
This states that C and XXjY are equivalent modulo a scale parameter
(the variance of the output variable) and a rotation (the precision
matrix of the input variables). In [14] an efﬁcient algorithm to
estimate the gradient and GOP matrix, C ~ given data for the
classiﬁcation setting was developed. We use this method in this paper.
The estimate of the GOP matrix C ~ is the covariance matrix of a
multivariate Gaussian random vector by construction. The inverse of
this matrix J ¼ C ~
 1 is by the theory of Gauss-Markov random ﬁelds
[19] the conditional independence matrix (the pseudo-inverse is used
when C ~ is degenerate),
Jij¼dependence between variables i and j j all other input variables
and the output variable.
Construction of pathway association graph: Given the list Gt of pathways
relevant to the t-th step in progression and the enrichment summary
statistic dataset St, this dataset is reduced by removing the enrich-
ment scores of all pathways not in Gt. The GOP estimate, C ~ t , given
this data is computed. This matrix is d 3 d where d is the number of
relevant pathways in Gt. The pseudo-inverse of this matrix At¼C ~ 1
t is
the pathway association graph for the t-th progression step.
Gene set reﬁnement and gene association graph: Not all genes in the
relevant gene sets, Gt, are differentially expressed between the two
stages of progression in step t. We reduce or reﬁne each of the
pathway gene sets to those genes most relevant in progression step t.
The following procedure is iterated for each of the relevant gene
set in Gt. Given the k-th pathway gene set the stratiﬁed data Dt is
reduced to the genes in this gene set. The GOP estimate, C ~
t, given this
data is computed. This matrix is d3d where d is the number of genes
in the k-th pathway in Gt. Genes corresponding to large diagonal
elements of the GOP matrix, jC ~ t
iij . s , are those most relevant to the
prediction and are the reﬁned set R. In this paper, the threshold s is
selected such that we obtain a speciﬁc number of genes.
The GOP estimate, C ~
t, is then reduced to only the genes in the
reﬁned gene set R. The pseudo-inverse of this matrix is the gene
association matrix ~ Ak that provides the dependence of the reﬁned
gene set.
Data analysis algorithm.
Input: data D, thresholds (s1, s2), gene sets C, RML algorithm M,
graph algorithm A, reﬁnement algorithm R.
Return: relevant gene sets fGtg
T
t¼1, pathway association graphs
fAtg
T
t¼1, reﬁned gene sets C





T ¼ number of steps in progression;
for t   to T do
/ / Stratify data by taking subset relevant in step t
Dt   D;
/ / Map Dt to enrichment summary statistics over gene sets
St ¼ S(Dt, C);
fðw0;wtÞg
T
t¼1   MðfStg
T
i¼1Þ; / / Apply RML to the summary statistics
/ / Select relevant gene sets over stages of progression
for t  1to T do
Gt ¼ Ø; Initialize relevant gene sets for stage t
for all elements of wt do if jwtij. s1 then add gene set i to Gt;
/ / Construct pathway association graphs
for t   1 to T do A
t   A(Gt,Dt);
//Reﬁne relevant gene sets
CR   RðfGt;Dtg
T
t¼1;C;s2Þ;
/ / Construct gene association graphs for reﬁned gene sets
for i ¼ 1 to jC
Rj do ~ A
i
  A(Dt, C
R);
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